19
Participants
Start Date
March 20, 2019
Primary Completion Date
June 21, 2021
Study Completion Date
February 21, 2022
Peposertib 50 mg
Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
Peposertib 100 mg
Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
Peposertib 150 mg
Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
Peposertib 250 mg
Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
Capecitabine
Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
Radiotherapy (RT)
Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
Northwell Health, Inc, Great Neck
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Montefiore Medical Center, The Bronx
Med. Univ. of South Carolina, Charleston
Greenville Hospital System University Medical Center (ITOR), Greenville
Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent, Columbus
University of Toledo Medical Center - Hematology/Oncology, Toledo
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
Yale University - Pediatric Respiratory Medicine, New Haven
Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona
Hospital Universitario 12 de Octubre - Servicio de Oncologia, Madrid
Hospital Regional Universitario de Malaga, Málaga
Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica, Valencia
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY